LEXXW
Income statement / Annual
Last year (2023), Lexaria Bioscience Corp.'s total revenue was $226,208.00,
a decrease of 11.43% from the previous year.
In 2023, Lexaria Bioscience Corp.'s net income was -$6.66 M.
See Lexaria Bioscience Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
08/31/2023 |
08/31/2022 |
08/31/2021 |
08/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
08/31/2015 |
08/31/2014 |
| Operating Revenue |
$226,208.00
|
$255,397.00
|
$722,738.00
|
$384,543.00
|
$222,610.00
|
$433,287.00
|
$63,639.00
|
$40,718.00
|
$14,702.00
|
$1.10 M
|
| Cost of Revenue |
$31,500.00 |
$71,841.00 |
$175,346.00 |
$99,378.00 |
$22,893.00 |
$25,185.00 |
$29,750.00 |
$45,615.00 |
$29,883.00 |
$795,204.00 |
| Gross Profit |
$194,708.00 |
$183,556.00 |
$547,392.00 |
$285,165.00 |
$199,717.00 |
$408,102.00 |
$33,889.00 |
-$4,897.00 |
-$15,181.00 |
$302,251.00 |
| Gross Profit Ratio |
0.86 |
0.72 |
0.76 |
0.74 |
0.9 |
0.94 |
0.53 |
-0.12 |
-1.03 |
0.28 |
| Research and Development
Expenses |
$3.67 M
|
$1.84 M
|
$1.26 M
|
$387,074.00
|
$555,730.00
|
$492,864.00
|
$54,185.00
|
$9,024.00
|
$146,466.00
|
$0.00
|
| General & Administrative
Expenses |
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.57 M
|
$3.13 M
|
$6.02 M
|
$1.63 M
|
$1.01 M
|
$1.49 M
|
$1.27 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$204,277.00
|
$515,360.00
|
$489,058.00
|
$209,034.00
|
$185,459.00
|
$276,560.00
|
$8,194.00
|
| Selling, General &
Administrative Expenses |
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.77 M
|
$3.64 M
|
$6.51 M
|
$1.84 M
|
$1.20 M
|
$1.76 M
|
$8,194.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$112,750.00 |
$60,550.00 |
$2,307.00 |
-$886.00 |
$4,602.00 |
-$22,664.00 |
$0.00 |
| Operating Expenses |
$6.73 M |
$7.57 M |
$6.23 M |
$4.27 M |
$4.26 M |
$7.01 M |
$1.90 M |
$1.21 M |
$1.91 M |
$8,194.00 |
| Cost And Expenses |
$6.76 M |
$7.64 M |
$6.41 M |
$4.37 M |
$4.28 M |
$7.03 M |
$1.92 M |
$1.26 M |
$1.94 M |
$803,398.00 |
| Interest Income |
$43,190.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$6,015.00 |
$2,250.00 |
$31,544.00 |
$267,357.00 |
| Depreciation &
Amortization |
$145,397.00
|
$146,914.00
|
$147,597.00
|
$146,092.00
|
$60,550.00
|
$2,307.00
|
$1,488.00
|
$619.00
|
-$22,664.00
|
$1.52 M
|
| EBITDA |
-$6.39 M
|
-$6.52 M
|
-$5.58 M
|
-$4.00 M
|
-$4.10 M
|
-$6.61 M
|
-$1.92 M
|
-$1.26 M
|
-$1.95 M
|
$294,057.00
|
| EBITDA Ratio |
-28.24 |
-28.36 |
-9.77 |
-9.83 |
-17.52 |
-15.23 |
-29.22 |
-29.84 |
-132.69 |
0.27 |
| Operating Income Ratio
|
-28.89
|
-28.91
|
-7.87
|
-10.12
|
-17.79
|
-15.23
|
-29.25
|
-29.85
|
-131.15
|
0.27
|
| Total Other
Income/Expenses Net |
-$178,503.00
|
-$764,614.00
|
$1.52 M
|
$0.00
|
-$228,060.00
|
-$8,968.00
|
-$6,015.00
|
-$34,698.00
|
-$55,058.00
|
-$355,229.00
|
| Income Before Tax |
-$6.71 M |
-$7.38 M |
-$4.16 M |
-$4.08 M |
-$4.16 M |
-$6.61 M |
-$1.93 M |
-$1.28 M |
-$1.98 M |
-$1.87 M |
| Income Before Tax Ratio
|
-29.67
|
-28.91
|
-5.76
|
-10.62
|
-18.68
|
-15.25
|
-30.32
|
-31.37
|
-134.9
|
-1.71
|
| Income Tax Expense |
$0.00 |
-$114,329.00 |
-$1.66 M |
-$54,286.00 |
$39,623.00 |
-$8,968.00 |
-$54,173.00 |
-$60,226.00 |
-$181,226.00 |
$294,057.00 |
| Net Income |
-$6.66 M |
-$7.27 M |
-$2.50 M |
-$4.03 M |
-$4.20 M |
-$6.60 M |
-$1.87 M |
-$1.21 M |
-$1.77 M |
-$1.87 M |
| Net Income Ratio |
-29.46 |
-28.46 |
-3.47 |
-10.48 |
-18.86 |
-15.23 |
-29.37 |
-29.83 |
-120.43 |
-1.71 |
| EPS |
-1.01 |
-1.24 |
-0.57 |
-1.45 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
-1.34 |
-0.0728 |
| EPS Diluted |
-1.01 |
-1.24 |
-0.57 |
-1.45 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
-1.34 |
-0.0728 |
| Weighted Average Shares
Out |
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
$1.32 M
|
$25.71 M
|
| Weighted Average Shares
Out Diluted |
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
$1.32 M
|
$25.71 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
